If a 3D protein is obtained with the inhibitor complex, its wild-type size may change completely. In this case, it seems correct to investigate the binding mode with the inhibitor molecule. If the protein to be investigated has only an inhibitor complex, what protein should I select in the PDB and in my activator molecule research, and what path should it follow?